Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore (Nasdaq: ECOR) announced that gammaCore will remain listed in the NHS Supply Chain catalogue for an additional two years, extending its availability through June 3, 2023. This listing allows NHS trusts to continuously procure gammaCore Sapphire™ (nVNS), facilitating better access for patients in the UK needing non-invasive vagus nerve stimulation for migraine and cluster headache treatments. The inclusion is pivotal for ensuring that this innovative therapy is accessible and cost-effective for healthcare organizations amid budgetary constraints.
electroCore (Nasdaq: ECOR) announced FDA clearance on February 12, 2021, for its gammaCore device, now allowing its use in treating migraines in adolescents aged 12 to 17. This label expansion covers acute and preventive treatment for various headache types. With an estimated 10% of school-age children experiencing migraines, this development positions gammaCore as a unique non-pharmaceutical treatment option. The clearance supports prior trials showing significant effectiveness in migraine management without acute medication reliance.
On February 11, 2021, electroCore, Inc. (Nasdaq: ECOR) announced the completion of patient enrollment in its SAVIOR-1 study, which evaluates non-invasive vagus nerve stimulation (nVNS) for COVID-19 patients experiencing respiratory symptoms. Conducted in Valencia, Spain, the trial enrolled 110 patients aged 18 and older, randomized to receive either nVNS with standard care or standard care alone. The study aims to assess clinical events, safety, and proinflammatory cytokine levels, with preliminary results expected soon and full results in a peer-reviewed publication later this year.
electroCore, Inc. (Nasdaq: ECOR) announced the publication of a peer-reviewed paper in Colorectal Disease, detailing a study on non-invasive vagus nerve stimulation (nVNS) for treating ileus after colorectal surgery. Conducted at St. James’s University Hospital with 40 subjects, the trial aimed to assess safety and feasibility. Results indicated nVNS was safe and improved several recovery metrics, such as reduced morphine use by 25.6% post-surgery. Future studies, including the TRANSIT study with 140 patients, aim to explore nVNS's potential further.
electroCore (Nasdaq: ECOR), a bioelectronic medicine company, will participate in a fireside chat at the BTIG Virtual MedTech Conference from February 17-19, 2021. The chat is scheduled for February 17 at 12:30 PM ET. A live webcast will be available on the company's website. The company focuses on non-invasive vagus nerve stimulation therapy to treat conditions such as cluster headaches and migraines.
electroCore (Nasdaq: ECOR) announced that gammaCore Sapphire (nVNS) is included in NHS England's new MedTech Funding Mandate Policy 2021/22, effective April 1, 2021. This policy supports NHS commissioners and providers in adopting NICE-approved technologies to enhance patient outcomes. It emphasizes that gammaCore could save the NHS up to £4,561,223 over five years. The policy aims for effective, affordable, and cost-saving innovations, transitioning from shorter renewal cycles to more stable reimbursement structures.
electroCore, Inc. (Nasdaq: ECOR) announced an agreement with RSK Medical Inc. to distribute its gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Canada. This partnership aims to provide treatment for patients with primary headache disorders, particularly migraines and cluster headaches. The agreement, with a three-year initial term, includes minimum purchase commitments. Both companies emphasize their commitment to improving patient access to innovative therapies.
electroCore, Inc. (Nasdaq: ECOR) announced that Health Improvement Scotland has published a Scottish Health Technology Group adaptation for NHS Scotland regarding the use of gammaCore for cluster headache treatment. This recommendation supports NICE guidelines from 2019, stating gammaCore can reduce attack frequency and intensity, improving patients' quality of life and saving £450 per patient in the first year. The adaptation allows for a three-month trial of gammaCore in NHS Scotland. The company aims to expand access to its treatment for cluster headache patients.
electroCore, Inc. (Nasdaq: ECOR) announced that the Centers for Medicare and Medicaid Services (CMS) published a new HCPCS code K1020 for its gammaCore Sapphire™ D device, effective April 1, 2021. This non-invasive vagus nerve stimulator code aims to enhance patient access to gammaCore therapy, which treats primary headache conditions. The decision reflects CMS’s recognition of the clinical and economic benefits of the gammaCore treatment, positioning the company for broader coverage opportunities.
electroCore (Nasdaq: ECOR) announced expected full-year 2020 revenue between $3.3M and $3.5M, reflecting over 40% growth from 2019's $2.4M. Q4 2020 net cash usage was $3.7M, better than the $4M guidance, and cash reserves at year-end totaled $22.6M. The company continues initiatives in COVID-19 and opioid use disorder treatments, alongside favorable data from the PREMIUM II migraine study. Expansion efforts included distribution agreements in Eastern Europe and government channels, despite challenges posed by COVID-19. Management expresses optimism for future growth opportunities.